Back to School: How biopharma can reboot drug development. Access exclusive analysis here
One-year data from an ongoing U.S. Phase II trial in 411 women showed that AMG 162 increased BMD at the lumbar
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury